Influence of myocardial region of interest definition on quantitative analysis of planar 123I-mIBG images

European Journal of Nuclear Medicine and Molecular Imaging

Volumn 40, Issue 4, 2013, Pages 558-564

  Jacobson, Arnold F ^a   Matsuoka, Dale T ^b  

^a GE HEALTHCARE   (United States)

^b DTM Consulting   (United States)

Author keywords

123I mIBG; Cardiac scintigraphy; Regions of interest; Sympathetic innervation

Indexed keywords

MIBG I 123; RADIOPHARMACEUTICAL AGENT; UNCLASSIFIED DRUG;

ARTICLE; DRUG UPTAKE; HEART; HEART MUSCLE; HEART SCINTISCANNING; HUMAN; IMAGE ANALYSIS; IMAGE QUALITY; MAJOR CLINICAL STUDY; MEDIASTINUM;

3-IODOBENZYLGUANIDINE; CASE-CONTROL STUDIES; DATA INTERPRETATION, STATISTICAL; HEART; HUMANS; MEDIASTINUM; MYOCARDIAL PERFUSION IMAGING; RADIOPHARMACEUTICALS; REFERENCE VALUES;

EID: 84875690984     PISSN: 16197070     EISSN: 16197089     Source Type: Journal    
DOI: 10.1007/s00259-012-2336-0     Document Type: Article

References (24)

1. Carrio I. Cardiac neurotransmission imaging. J Nucl Med. 2001;42:1062-76.
2. Yamashina S, Yamazaki J. Neuronal imaging using SPECT. Eur J Nucl Med Mol Imaging. 2007;34:939-50.
3. Verberne HJ, Brewster LM, Somsen GA, Eck-Smit BL. Prognostic value of myocardial 123I-metaiodobenzylguanidine (MIBG) parameters in patients with heart failure: a systematic review. Eur Heart J. 2008;29:1147-59.
4. Flotats A, Carrio I. Cardiac neurotransmission SPECT imaging. J Nucl Cardiol. 2004;11:587-602.
5. Higuchi T, Schwaiger M. Imaging cardiac neuronal function and dysfunction. Curr Cardiol Rep. 2006;8:131-8.
6. Henneman MM, Bengel FM, van der Wall EE, Knuuti J, Bax JJ. Cardiac neuronal imaging: application in the evaluation of cardiac disease. J Nucl Cardiol. 2008;15:442-55.
7. Merlet P, Valette H, Dubois-Rande JL, Moyse D, Duboc D, Dove P, et al. Prognostic value of cardiac metaiodobenzylguanidine imaging in patients with heart failure. J Nucl Med. 1992;33:471-7.
8. Nakata T, Miyamoto K, Doi A, Sasao H, Wakabayashi T, Kobayashi H, et al. Cardiac death prediction and impaired cardiac sympathetic innervation assessed by MIBG in patients with failing and nonfailing hearts. J Nucl Cardiol. 1998;5:579-90.
9. Kasama S, Toyama T, Kumakura H, Takayama Y, Ichikawa S, Suzuki T, et al. Spironolactone improves cardiac sympathetic nerve activity and symptoms in patients with congestive heart failure. J Nucl Med. 2002;43:1279-85.
10. Agostini D, Belin A, Amar MH, Darlas Y, Hamon M, Grollier G, et al. Improvement of cardiac neuronal function after carvedilol treatment in dilated cardiomyopathy: a 123I-MIBG scintigraphic study. J Nucl Med. 2000;41:845-51.
11. Cohen-Solal A, Esanu Y, Logeart D, Pessione F, Dubois C, Dreyfus G, et al. Cardiac metaiodobenzylguanidine uptake in patients with moderate chronic heart failure: relationship with peak oxygen uptake and prognosis. J Am Coll Cardiol. 1999;33:759-66.
12. Jacobson AF, Senior R, Cerqueira MD, Wong ND, Thomas GS, Lopez VA, et al. Myocardial iodine-123 meta-iodobenzylguanidine imaging and cardiac events in heart failure. Results of the prospective ADMIRE-HF study. J Am Coll Cardiol. 2010;55:2212-21.
13. Okuda K, Nakajima K, Hosoya T, Ishikawa T, Konishi T, Matsubara K, et al. Semi-automated algorithm for calculating heart-to-mediastinum ratio in cardiac iodine-123 MIBG imaging. J Nucl Cardiol. 2011;18:82-9.
14. Somsen GA, Borm JJ, Dubois EA, Schook MB, van der Wall EE, van Royen EA. Cardiac 123I-MIBG uptake is affected by variable uptake in reference regions: implications for interpretation in clinical studies. Nucl Med Commun. 1996;17:872-6.
15. Verberne HJ, Feenstra C, de Jong WM, Somsen GA, Eck-Smit BL, Busemann SE. Influence of collimator choice and simulated clinical conditions on 123I-MIBG heart/mediastinum ratios: a phantom study. Eur J Nucl Med Mol Imaging. 2005;32:1100-7.
16. Verberne HJ, Somsen GA, Povinec P, Eck-Smit BL, Jacobson AF. Impact of mediastinal, liver and lung (123)I-metaiodobenzylguanidine ((123)I-MIBG) washout on calculated (123)I-MIBG myocardial washout. Eur J Nucl Med Mol Imaging. 2009;36:1322-8.
17. Verberne HJ, Somsen GA, Eck-Smit BL. 123I-meta-iodobenzylguanidine in patients with chronic heart failure: technical aspects, conceptual issues, and future prospects. Nucl Med Commun. 2009;30:411-4.
18. Verberne HJ, Habraken JBA, van Eck-Smit BLF, Agostini D, Jacobson AF. Variations in 123I-metaiodobenzylguanidine (MIBG) late heart mediastinal ratios in chronic heart failure: a need for standardization and validation. Eur J Nucl Med Mol Imaging. 2008;35:547-53.
19. Flotats A, Carrio I, Agostini D, Le Guludec D, Marcassa C, Schaffers M, et al. Proposal for standardization of (123)I-metaiodobenzylguanidine (MIBG) cardiac sympathetic imaging by the EANM Cardiovascular Committee and the European Council of Nuclear Cardiology. Eur J Nucl Med Mol Imaging. 2010;37:1802-12.
20. Somsen GA, Verberne HJ, Fleury E, Righetti A. Normal values and within-subject variability of cardiac I-123 MIBG scintigraphy in healthy individuals: implications for clinical studies. J Nucl Cardiol. 2004;11:126-33.
21. Agostini D, Verberne HJ, Burchert W, Knuuti J, Povinec P, Sambuceti G, et al. 123I-mIBG myocardial imaging for assessment of risk for a major cardiac event in heart failure patients: insights from a retrospective European multi-center study. Eur J Nucl Med Mol Imaging. 2008;35:535-46.
22. Bax JJ, Kraft O, Buxton AE, Fjeld JG, Parízek P, Agostini D, et al. 123I-mIBG scintigraphy to predict inducibility of ventricular arrhythmias on cardiac electrophysiology testing. A prospective multicenter pilot study. Circ Cardiovasc Imaging. 2008;1:131-40.
23. Jacobson AF, Lombard J, Banerjee G, Camici P. 123I-mIBG scintigraphy to predict risk for adverse cardiac outcomes in heart failure patients: design of two prospective multicenter international trials. J Nucl Cardiol. 2009;16:113-21.
24. Somsen GA, Borm JJ, de Milliano PA, van Vlies B, Dubois EA, van Royen EA. Quantitation of myocardial iodine-123 MIBG uptake in SPET studies: a new approach using the left ventricular cavity and a blood sample as a reference. Eur J Nucl Med. 1995;22:1149-54.